bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.
bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance
14 January, 2020
bioMérieux – Third-Quarter 2019 Business Review
22 October, 2019
bioMérieux – First-Half 2019 Results
04 September, 2019
bioMérieux – 2018 Financial Results
27 February, 2019
Sale of bioMérieux Australia's Clinical PPM business
22 January, 2019
bioMérieux – Business review for the nine months ended
30 September, 2018